Author
Effie W. Petersdorf
Other affiliations: University of Oxford, National Taiwan University, Seattle Cancer Care Alliance ...read more
Bio: Effie W. Petersdorf is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Transplantation & Human leukocyte antigen. The author has an hindex of 67, co-authored 234 publications receiving 18917 citations. Previous affiliations of Effie W. Petersdorf include University of Oxford & National Taiwan University.
Papers published on a yearly basis
Papers
More filters
Anthony Nolan1, University of Oxford2, Biomedical Primate Research Centre3, Kettering University4, Hoffmann-La Roche5, University of Texas MD Anderson Cancer Center6, Fred Hutchinson Cancer Research Center7, University of Washington8, University of California, Los Angeles9, Hallym University10, University of Geneva11, National Marrow Donor Program12, Medical University of Vienna13, Stanford University14, Harvard University15, University of Cambridge16
TL;DR: This report documents the additions and revisions to the nomenclature of HLA specificities following the principles established in previous reports.
Abstract: The WHO Nomenclature Committee for Factors of the HLA System met following the 14th International HLA and Immunogenetics Workshop in Melbourne, Australia in December 2005 and Buzios, Brazil during the 15th International HLA and Immunogenetics Workshop in September 2008. This report documents the additions and revisions to the nomenclature of HLA specificities following the principles established in previous reports (1–18).
2,390 citations
Fred Hutchinson Cancer Research Center1, Center for International Blood and Marrow Transplant Research2, University of California, San Francisco3, National Marrow Donor Program4, University of Texas MD Anderson Cancer Center5, Thomas Jefferson University Hospital6, Georgetown University Medical Center7, University of Minnesota8, University of New Mexico9
TL;DR: In multivariate modeling, patient age, race, disease stage, and cytomegalovirus status were as predictive of survival as donor HLA matching, and high-resolution DNA matching for HLA-A, -B, -C, and -DRB1 alleles is associated with higher rates of survival.
1,105 citations
TL;DR: It is concluded that matching for HLA-C should be incorporated into algorithms for unrelated donor selection, and when clinical circumstances allow, high-resolution class I typing may help optimize donor selection and improve outcome.
689 citations
TL;DR: Transplantation of marrow from an HLA-matched, unrelated donor is safe and effective therapy for selected patients with chronic myeloid leukemia.
Abstract: Background Chronic myeloid leukemia can be cured by marrow transplantation from an HLA-identical sibling donor. The use of transplants from unrelated donors is an option for the 70 percent of patients without an HLA-identical sibling, but the morbidity and mortality associated with such transplants have been cause for concern. We analyzed the safety and efficacy of transplants from unrelated donors for the treatment of chronic myeloid leukemia and identified variables that predict a favorable outcome. Methods Between May 1985 and December 1994, 196 patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase received marrow transplants from unrelated donors. Results The median follow-up was 5 years (range, 1.2 to 10.1). Graft failure occurred in 5 percent of patients who could be evaluated. Acute graft-versus-host disease of grade III or IV severity was observed in 35 percent of patients who received HLA-matched transplants, and the estimated cumulative incidence of relapse at ...
615 citations
TL;DR: The results suggest that the mechanisms involved in acute and chronic GVHD are not entirely congruent and that chronicGVHD is not simply the end stage of acute GV HD.
521 citations
Cited by
More filters
Vanderbilt University Medical Center1, Medical University of Vienna2, University of Minnesota3, National Institutes of Health4, University of Regensburg5, Mayo Clinic6, Brigham and Women's Hospital7, Fred Hutchinson Cancer Research Center8, BC Cancer Agency9, State University of Campinas10, Stanford University11, University of Michigan12, Harvard University13, Johns Hopkins University School of Medicine14
TL;DR: The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence, and focuses attention on the causes of organ-specific abnormalities to chronic GVHD.
4,122 citations
University of Ulm1, University of Rome Tor Vergata2, Fred Hutchinson Cancer Research Center3, University of Münster4, University of Wales5, University of Chicago6, Nagoya University7, Leipzig University8, VU University Medical Center9, Northwestern University10, Erasmus University Medical Center11, Ohio State University12
TL;DR: An international expert panel is provided to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials.
3,000 citations
Veterans Health Administration1, Medical University of Vienna2, University of Minnesota3, University of Regensburg4, National Institutes of Health5, Mayo Clinic6, Harvard University7, Fred Hutchinson Cancer Research Center8, University of British Columbia9, Stanford University10, University of Michigan11, Johns Hopkins University12
TL;DR: In this article, the authors proposed a new clinical scoring system (0-3) that describes the extent and severity of chronic graft-versus-host disease for each organ or site at any given time, taking functional impact into account.
2,883 citations
[...]
TL;DR: The structure, function, and ligand specificity of the receptors responsible for NK cell recognition are reviewed and the role of EMT inNK cell recognition is reviewed.
Abstract: The integrated processing of signals transduced by activating and inhibitory cell surface receptors regulates NK cell effector functions. Here, I review the structure, function, and ligand specificity of the receptors responsible for NK cell recognition.
2,724 citations
Anthony Nolan1, University of Oxford2, Biomedical Primate Research Centre3, Kettering University4, Hoffmann-La Roche5, University of Texas MD Anderson Cancer Center6, Fred Hutchinson Cancer Research Center7, University of Washington8, University of California, Los Angeles9, Hallym University10, University of Geneva11, National Marrow Donor Program12, Medical University of Vienna13, Stanford University14, Harvard University15, University of Cambridge16
TL;DR: This report documents the additions and revisions to the nomenclature of HLA specificities following the principles established in previous reports.
Abstract: The WHO Nomenclature Committee for Factors of the HLA System met following the 14th International HLA and Immunogenetics Workshop in Melbourne, Australia in December 2005 and Buzios, Brazil during the 15th International HLA and Immunogenetics Workshop in September 2008. This report documents the additions and revisions to the nomenclature of HLA specificities following the principles established in previous reports (1–18).
2,390 citations